Works by Yang, Jianning


Results: 12
    1

    IQ Survey Results on Current Industry Practices—Part 1: Immunogenicity Risk Assessment.

    Published in:
    Clinical Pharmacology & Therapeutics, 2025, v. 117, n. 6, p. 1596, doi. 10.1002/cpt.3568
    By:
    • Grimaldi, Christine;
    • Richards, Susan;
    • Baltrukonis, Daniel;
    • Sims Belouski, Shelley;
    • Coble, Kelly;
    • Dholakiya, Sanjay L.;
    • Grudzinska‐Goebel, Joanna;
    • Kolaitis, Gerry;
    • Leu, Jocelyn H.;
    • Luo, Linlin;
    • Lowe, Stephen;
    • Niu, Tao;
    • Toft‐Hansen, Henrik;
    • Yang, Jianning;
    • Wu, Benjamin
    Publication type:
    Article
    2
    3
    4
    5
    6
    7
    8

    Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20<sup>+</sup> lymphoid malignancies.

    Published in:
    British Journal of Haematology, 2015, v. 170, n. 5, p. 669, doi. 10.1111/bjh.13487
    By:
    • Roberts, Andrew W.;
    • Advani, Ranjana H.;
    • Kahl, Brad S.;
    • Persky, Daniel;
    • Sweetenham, John W.;
    • Carney, Dennis A.;
    • Yang, Jianning;
    • Busman, Todd B.;
    • Enschede, Sari H.;
    • Humerickhouse, Roderick A.;
    • Seymour, John F.
    Publication type:
    Article
    9

    Considerations for Industry—Preparing for the FDA Model‐Informed Drug Development (MIDD) Paired Meeting Program.

    Published in:
    Clinical Pharmacology & Therapeutics, 2024, v. 116, n. 2, p. 282, doi. 10.1002/cpt.3245
    By:
    • Galluppi, Gerald R.;
    • Ahamadi, Malidi;
    • Bhattacharya, Souvik;
    • Budha, Nageshwar;
    • Gheyas, Ferdous;
    • Li, Chi‐Chung;
    • Chen, Yuan;
    • Dosne, Anne‐Gaëlle;
    • Kristensen, Niels Rode;
    • Magee, Mindy;
    • Samtani, Mahesh N.;
    • Sinha, Vikram;
    • Taskar, Kunal;
    • Upreti, Vijay V.;
    • Yang, Jianning;
    • Cook, Jack
    Publication type:
    Article
    10
    11
    12